In a report released today, Derek Jellinek from Morgans maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, with a price target of A$40.97.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Jellinek covers the Healthcare sector, focusing on stocks such as Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, Cochlear , and CSL. According to TipRanks, Jellinek has an average return of -8.9% and a 32.79% success rate on recommended stocks.
In addition to Morgans, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh also received a Buy from Jarden’s Steven Wheen in a report issued on July 8. However, yesterday, Citi downgraded Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (ASX: RMD) to a Hold.
Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of A$1.42 billion and a net profit of A$395.1 million. In comparison, last year the company earned a revenue of A$1.29 billion and had a net profit of A$365.04 million
